HK Stock Market Move | TYK MEDICINES-B (02410) rose by over 4% in the afternoon. Adotinib mesylate tablets (TY-9591 tablets) are planned to be included in priority review.

TYK MEDICINES-B (02410) rose by over 4% in the afternoon, with a 3.87% increase to 14.21 Hong Kong dollars as of press time, with a turnover of 59.4029 million Hong Kong dollars. On the news front, Tongyuan Kang Pharmaceutical released an announcement that the company's new drug TY-9591 tablets, a Class 1 new drug sulfonate edotinib, is proposed to be included in the priority review variety list by the National Medical Products Administration (NMPA) Drug Evaluation Center. The proposed indication is for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion (19DEL) or exon 21 (L858R) substitution mutation, and with central nervous system (CNS) metastasis as first-line treatment.